

## General Information

Name: Prof. Dr. med. Stephan Stilgenbauer  
Date of Birth: 27.11.1966  
Gender: Male  
Address: Department of Internal Medicine III, Ulm University  
Albert-Einstein-Allee 23, 89081 Ulm, Germany  
Phone: +49 731 500 45521  
E-Mail: stephan.stilgenbauer@uniklinik-ulm.de  
Current Position: Group leader, Department of Internal Medicine III, Ulm University  
and  
Acting Chair, Department of Internal Medicine 1, Saarland University

## Academic Education

1994 Medical Licensing Examination  
1987-1994 Medical School, Heidelberg University

## Academic Degrees

2005 Professor of Medicine (*Außerplanmäßige Professur*)  
2002 Postdoctoral Thesis (*Habilitation*), Internal Medicine, Ulm University,  
Mentor: Prof. Hartmut Döhner  
1994 Doctoral Thesis (*Dr. med.*), Medicine, Heidelberg University, Advisor:  
Prof. Peter P. Nawroth

## Professional Experience

Since 2018 Group Leader, Department of Internal Medicine III, Ulm University  
and  
Acting Chair, Department of Internal Medicine 1, Saarland University  
2003-2018 Apl. Professor and Attending Physician (*Oberarzt*), Department of  
Internal Medicine III, Ulm University  
Since 1999 Group Leader of the CLL research laboratory and central reference  
laboratory genetics of the GCLLSG  
2004 Boards in Hematology and Medical Oncology  
2002 Boards in Internal Medicine  
1999-2002 Fellowship in Internal Medicine, Hematology, Oncology,  
Rheumatology, Infectious Diseases; Department of Internal Medicine  
III, Ulm University (Director: Prof. Dr. H. Döhner)  
1996-1998 Postdoctoral Research Fellow at the Department "Organization of  
Complex Genomes" of the Deutsche Krebsforschungszentrum,  
Heidelberg, Germany (Head: Prof. Peter Lichter)  
1994-1999 Residency in Internal Medicine, Hematology, Oncology, Rheumatology;  
Department of Internal Medicine V, Heidelberg University (Director:  
Prof. W. Hunstein, Prof. R. Haas, Prof. A. D. Ho)

## Miscellaneous

### Awards, Honors, Positions:

Since 2018 Web of Science Group Highly Cited Researcher – Ranking among the  
top 1% of researchers for most cited documents, in their specific field  
2012 Paul Martini Preis der Deutschen Gesellschaft für Innere Medizin  
Since 2012 Chairman, Certificate of Competence in Lymphoma, European School  
of Oncology  
2011-2019 Speaker of the "Else Kröner Forschungskolleg Ulm", funded by the Else  
Kröner Fresenius Stiftung

Since 2010	Module Director, Module 4 (Advanced/Integrated Therapies) Master Online Advanced Oncology Program, Ulm University
2008	Walther und Christine Richtzenhain Award of the German Cancer Research Center, Heidelberg
2006	Merckle Research Award, Ulm University
2002	Artur Pappenheim Award, German Society of Hematology and Oncology
2001	Leukemia Research Award, Franziska Kolb Foundation, Ulm University

## Publications

1. Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner CM, Langerak AW, Kreuzer KA, Ritgen M, Goede V, Stilgenbauer S, Mobasher M, Hallek M. Venetoclax and Obinutuzumab in patients with CLL and coexisting conditions. **N Engl J Med.** 2019;380(23):2225-36.
2. Mallm JP, Iskar M, Ishaque N, Klett LC, Kugler SJ, Muino JM, Teif VB, Poos AM, Großmann S, Erdel F, Tavernari D, Koser SD, Schumacher S, Brors B, König R, Remondini D, Vingron M, Stilgenbauer S, Lichter P, Zapatka M, Mertens D, Rippe K. Linking aberrant chromatin features in chronic lymphocytic leukemia to transcription factor networks. **Mol Syst Biol.** 2019;22;15(5):e8339.
3. Tausch E, Close W, Dolnik A, Bloehdorn J, Chyla B, Bullinger L, Döhner H, Mertens D, Stilgenbauer S. Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. **Haematologica.** 2019 Apr 19. [Epub ahead of print]
4. Scheffold A, Jebaraj BMC, Tausch E, Bloehdorn J, Ghia P, Yahiaoui A, Dolnik A, Blätte TJ, Bullinger L, Dheenadayalan RP, Li L, Schneider C, Chen SS, Chiorazzi N, Dietrich S, Seiffert M, Tannheimer S, Döhner H, Mertens D, Stilgenbauer S. IGF1R as druggable target mediating PI3K- $\delta$  inhibitor resistance in a murine model of chronic lymphocytic leukemia. **Blood.** 2019 Apr 22. [Epub ahead of print]
5. López C, Kleinheinz K, Aukema SM, Rohde M, Bernhart SH, Hübschmann D, Wagener R, Toprak UH, Raimondi F, Kreuz M, Waszak SM, Huang Z, Sieverling L, Paramasivam N, Seufert J, Sungalee S, Russell RB, Bausinger J, Kretzmer H, Ammerpohl O, Bergmann AK, Binder H, Borkhardt A, Brors B, Claviez A, Doose G, Feuerbach L, Haake A, Hansmann ML, Hoell J, Hummel M, Korbelt JO, Lawrenz C, Lenze D, Radlwimmer B, Richter J, Rosenstiel P, Rosenwald A, Schilhabel MB, Stein H, Stilgenbauer S, Stadler PF, Szczepanowski M, Weniger MA, Zapatka M, Eils R, Lichter P, Loeffler M, Möller P, Trümper L, Klapper W; ICGC MMML-Seq Consortium, Hoffmann S, Küppers R, Burkhardt B, Schlesner M, Siebert R. Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. **Nat Commun.** 2019;10(1):1459.
6. Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Tausch E, Cramer P, Huang J, Mitra S, Hallek M, O'Brien SM, Stilgenbauer S. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. **J Clin Oncol.** 2019;37(16):1391-1402.
7. Close V, Close W, Kugler SJ, Reichenzeller M, Yosifov DY, Bloehdorn J, Pan L, Tausch E, Westhoff MA, Döhner H, Stilgenbauer S, Oswald F, Mertens D. FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL. **Blood.** 2019;133(8):830-39.
8. Jebaraj BMC, Tausch E, Landau DA, Bahlo J, Robrecht S, Taylor-Weiner AN, Bloehdorn J, Scheffold A, Mertens D, Böttcher S, Kneba M, Jäger U, Zenz T, Wenger MK, Fingerle-Rowson G, Wendtner C, Fink AM, Wu CJ, Eichhorst B, Fischer K, Hallek M, Döhner H, Stilgenbauer S. Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia. **Leukemia.** 2019 Mar 25. [Epub ahead of print].
9. Scheffold A, Jebaraj BM, Jaramillo S, Tausch E, Steinbrecher D, Hahn M, Böttcher S, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P, Stilgenbauer S. Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial. **Br J Haematol.** 2017;179(2):342-46.

10. Landau DA\*, Tausch E\*, Taylor-Weiner AN\*, Stewart, C, Reiter JG, Bahlo J, Kluth S, Bozic I, Lawrence M, Böttcher S, Cibulskis K, Mertens D, Sougnez C, Rosenberg M, Hess JM, Carter SL, Edelman J, Kless S, Fink A, Fischer K, Gabriel S, Lander E, Nowak MA, Döhner H, Hallek M\*, Neuberg D\*, Getz G\*, Stilgenbauer S\*, Wu CJ\*. Somatic mutations driving chronic lymphocytic leukemia and their evolution in disease progression and relapse. **Nature**. 2015;526(7574):525-30.  
\*Equal contribution